Sigfred Ian R Alpajaro1, Jerad A K Harris2, Christopher P Evans3. 1. Department of Urology, University of California Davis Medical Center, Sacramento, CA, 95817, USA. sialpajaro@ucdavis.edu. 2. University of California Davis School of Medicine, Sacramento, CA, 95817, USA. 3. Department of Urology, University of California Davis Medical Center, Sacramento, CA, 95817, USA.
Abstract
BACKGROUND: Non-metastatic castration resistant prostate cancer (M0CRPC) is a heterogenous disease state affecting an estimated 100,000 men in the United States. Development of more sensitive modalities for detection of metastasis has altered the landscape of advanced prostate cancer, but M0CRPC has remained a condition that previously lacked FDA-approved treatment. The emerging data on new generation Androgen Receptor (AR) pathway inhibitors should address this gap in the management of such patients. METHODS: We reviewed and summarized the current literature for the definition, diagnosis and treatment of M0CRPC. We highlight the results of recent Phase III trials that show significant impact on the outcomes of M0CRPC. RESULTS: Androgen deprivation therapy remains the foundation of therapy for M0CRPC. Recently published Phase III trials provided data on improved progression free survival when ADT is augmented with newer AR pathway inhibitors. The SPARTAN trial showed that metastasis-free survival (MFS) for patients treated with apalutamide plus ADT is 40.5 months compared to 16.2 months for patients who received standard ADT plus placebo, a 72% reduction in the risk of distant metastasis or death in apalutamide plus ADT compared to ADT plus placebo. The PROSPER trial demonstrated that MFS for patients treated with enzalutamide plus ADT was 36.6 months compared to 14.7 months for patients who received standard ADT only indicating a 71% reduction in the risk of developing metastatic CRPC or death compared to ADT alone. The ARAMIS trial on darolutamide, another AR pathway inhibitor, is also ongoing, and can potentially be another fitting option for M0CRPC. CONCLUSION: The recent Phase III trials SPARTAN and PROPSER demonstrate effective treatment options for the M0CRPC disease state that has historically lacked treatment from high level evidence. In particular, an FDA-approved treatment, Apalutamide, can finally be offered for M0CRPC patients. The newer AR pathway inhibitors should provide a basis for further investigation into treatments for M0CRPC.
BACKGROUND: Non-metastatic castration resistant prostate cancer (M0CRPC) is a heterogenous disease state affecting an estimated 100,000 men in the United States. Development of more sensitive modalities for detection of metastasis has altered the landscape of advanced prostate cancer, but M0CRPC has remained a condition that previously lacked FDA-approved treatment. The emerging data on new generation Androgen Receptor (AR) pathway inhibitors should address this gap in the management of such patients. METHODS: We reviewed and summarized the current literature for the definition, diagnosis and treatment of M0CRPC. We highlight the results of recent Phase III trials that show significant impact on the outcomes of M0CRPC. RESULTS: Androgen deprivation therapy remains the foundation of therapy for M0CRPC. Recently published Phase III trials provided data on improved progression free survival when ADT is augmented with newer AR pathway inhibitors. The SPARTAN trial showed that metastasis-free survival (MFS) for patients treated with apalutamide plus ADT is 40.5 months compared to 16.2 months for patients who received standard ADT plus placebo, a 72% reduction in the risk of distant metastasis or death in apalutamide plus ADT compared to ADT plus placebo. The PROSPER trial demonstrated that MFS for patients treated with enzalutamide plus ADT was 36.6 months compared to 14.7 months for patients who received standard ADT only indicating a 71% reduction in the risk of developing metastatic CRPC or death compared to ADT alone. The ARAMIS trial on darolutamide, another AR pathway inhibitor, is also ongoing, and can potentially be another fitting option for M0CRPC. CONCLUSION: The recent Phase III trials SPARTAN and PROPSER demonstrate effective treatment options for the M0CRPC disease state that has historically lacked treatment from high level evidence. In particular, an FDA-approved treatment, Apalutamide, can finally be offered for M0CRPC patients. The newer AR pathway inhibitors should provide a basis for further investigation into treatments for M0CRPC.
Authors: Rodolfo Borges Dos Reis; Alejandro Alías-Melgar; Andrés Martínez-Cornelio; Silvia P Neciosup; Juan Pablo Sade; Marcos Santos; Gustavo Martin Villoldo Journal: Cancer Control Date: 2020 Jan-Dec Impact factor: 3.302
Authors: Fernando Maluf; Andrey Soares; Guilherme Avanço; Aline Lury Hada; Ana Paula Garcia Cardoso; Arie Carneiro; Daniel Herchenhorn; Denis Leonardo Fontes Jardim; Fabio Augusto Schutz; Fabio Roberto Kater; Felipe Moraes Toledo Pereira; Fernando Sabino Marques Monteiro; Igor Alexandre Protzner Morbeck; João Francisco Navarro Reolon; Karine Martins da Trindade; Livia Maria Querino da Silvo Andrade; Lucas Mendes Nogueira; Renato Furoni; Ricardo Azze Natel; Rodolfo Borges Dos Reis; Rodrigo Nogueira Fogace; Vinicius Carrera Souza Journal: Int Braz J Urol Date: 2021 Mar-Apr Impact factor: 1.541
Authors: Sijie Tang; Xueqi Lian; Jiajia Jiang; Huiying Cheng; Jiaqian Guo; Can Huang; Hong Meng; Xiaohua Li Journal: Front Cell Dev Biol Date: 2020-10-26